肝移植后急性肾损伤(acute kidney injury,AKI)的发生率为48%～91%,影响受者的预后。发生AKI后接受肾脏替代治疗受者的病死率从术后90d的40%增至术后1年的54%。近来的研究显示血清粒细胞明胶酶相关脂质运载蛋白(neutrophil gelatinase-associated lipocalin,NGAL)和半胱氨酸蛋白酶抑制剂-C(cystatin C)均能较好地预测AKI的发生。因此,英国研究者比较了NGAL和cystatin C与标准肾功能评价指标血清肌酐(sCr)和估算肾小 The incidence of acute kidney injury (AKI) after liver transplantation is 48% ~ 91%, which affects the prognosis of the recipients. The mortality rate of patients receiving renal replacement therapy after AKI increased from 40% at 90 days after surgery to 54% at 1 year after surgery. Recent studies have shown that neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C can predict AKI well. Therefore, the British researchers compared NGAL and cystatin C with the standard renal function evaluation index serum creatinine (sCr) and estimated renal